Literature DB >> 28875289

[Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology].

C Rose1.   

Abstract

The updated S3 guidelines on malignant melanoma were established in August 2016. The principles of diagnostics and classification are based on the histopathological results from the primary tumor and if necessary the sentinel lymph nodes. The most important factor for prognosis is the tumor thickness according to Breslow and the detection of sentinel node micrometastases. The surgical safety margin after excision is dependent on the tumor thickness. Furthermore, ulceration of the primary tumor and presence of mitosis in melanomas less than 1 mm in thickness are also considered in the T‑classification. The sentinel lymph nodes should be prepared according to established procedures using HE staining and immunohistochemical methods. The largest tumor diameter of a micrometastasis should be measured in tenths of a millimeter (Rotterdam classification). Molecular pathology testing for mutations in the BRAF and NRAS oncogenes should be carried out in patients with metastatic disease or surgically non-resectable tumors. In addition c-KIT mutations should be tested in acral lentiginous and mucosal melanomas. Treatment with signal transduction inhibitors is possible when mutations have been detected.

Entities:  

Keywords:  Metastasis; Mutations; Oncogenes; Sentinal lymph node biopsy; TNM staging

Mesh:

Substances:

Year:  2017        PMID: 28875289     DOI: 10.1007/s00105-017-4046-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  20 in total

1.  [Sentinel lymph node biopsy and its diagnostic and therapeutic importance].

Authors:  L Kofler; A S Yazdi
Journal:  Hautarzt       Date:  2014-11       Impact factor: 0.751

Review 2.  [Histological spectrum of malignant melanoma].

Authors:  T Brenn
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

3.  Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom.

Authors:  Katharina C Kähler; Jessica C Hassel; Lucie Heinzerling; Carmen Loquai; Rotraut Mössner; Selma Ugurel; Lisa Zimmer; Ralf Gutzmer
Journal:  J Dtsch Dermatol Ges       Date:  2016-07       Impact factor: 5.584

Review 4.  Checkpoint-Inhibitoren in der Immuntherapie: Ein Meilenstein in der Behandlung des malignen Melanoms.

Authors:  Sophia M Wilden; Berenice M Lang; Peter Mohr; Stephan Grabbe
Journal:  J Dtsch Dermatol Ges       Date:  2016-07       Impact factor: 5.584

Review 5.  AJCC melanoma staging update: impact on dermatopathology practice and patient management.

Authors:  Adriano Piris; Martin C Mihm; Lyn M Duncan
Journal:  J Cutan Pathol       Date:  2011-03-09       Impact factor: 1.587

6.  The magic of numbers: malignant melanoma between science and pseudoscience.

Authors:  Wolfgang Weyers
Journal:  Am J Dermatopathol       Date:  2011-06       Impact factor: 1.533

7.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

8.  Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision.

Authors:  Helene Nortvig Abrahamsen; Stephen J Hamilton-Dutoit; Jørn Larsen; Torben Steiniche
Journal:  Cancer       Date:  2004-04-15       Impact factor: 6.860

9.  Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.

Authors:  Abbas Agaimy; Katja Specht; Robert Stoehr; Thomas Lorey; Bruno Märkl; Gerald Niedobitek; Melanie Straub; Thomas Hager; Anna-Carinna Reis; Bastian Schilling; Regine Schneider-Stock; Arndt Hartmann; Thomas Mentzel
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

10.  Mitoserate beim primären Melanom: Interobserver- und Intraobserver-Reproduzierbarkeit am HE-Schnitt und in der Immunhistologie.

Authors:  Claus Garbe; Thomas K Eigentler; Jürgen Bauer; Norbert Blödorn-Schlicht; Lorenzo Cerroni; Falko Fend; Markus Hantschke; Peter Kurschat; Heinz Kutzner; Dieter Metze; Volker Mielke; Harald Preßler; Michael Reusch; Ursula Reusch; Rudolf Stadler; Michael Tronnier; Amir Yazdi; Gisela Metzler
Journal:  J Dtsch Dermatol Ges       Date:  2016-09       Impact factor: 5.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.